What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Ji Guang Wang, Yook Chin Chia, Chen Huan Chen, Sungha Park, Satoshi Hoshide, Naoko Tomitani, Tomoyuki Kabutoya, Jinho Shin, Yuda Turana, Arieska Ann Soenarta, Jam Chin Tay, Peera Buranakitjaroen, Jennifer Nailes, Huynh Van Minh, Saulat Siddique, Jorge Sison, Guru Prasad Sogunuru, Apichard Sukonthasarn, Boon Wee Teo, Narsingh VermaYu Qing Zhang, Tzung Dau Wang, Kazuomi Kario

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalJournal of Clinical Hypertension
Volume22
Issue number3
DOIs
Publication statusPublished - 2020 Mar 1

Bibliographical note

Funding Information:
JG Wang received consulting and lecture fees from Bayer, Omron, Salubris, Servier, and Takeda. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation, has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International, and has received grants for clinical research from Microlife Co., Ltd. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer, and CCL. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. JC Tay has received advisory board and consultant honoraria from Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. All other authors report no potential conflicts of interest in relation to this article.

Funding Information:
JG Wang was financially supported by grants from the National Natural Science Foundation of China (grants 81170245 and 91639203) and the State Ministry of Science and Technology (2018YFC1704902), Beijing, China and the Shanghai Commissions of Science and Technology (15XD1503200) and Health (grant 15GWZK0802 and a special grant for “leading academics”), Shanghai, China.

Publisher Copyright:
© 2020 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?'. Together they form a unique fingerprint.

Cite this